tradingview
Weekly Recap: ANDA for generic Advair Diskus and Q1 profit down 34%
Cipla Ltd (NSE:CIPLA) plans a Q2 FY2026/27 U.S. launch of the first dry‑powder inhaler from its U.S. plant after FDA ANDA approval for all three strengths of generic Advair Diskus into a ~$908M market, even as Q1 net profit fell 34% YoY despite revenue growth.Previous Week RecapThis is an AI-genera…